China Imatinib Mesylate (Novartis) Investigation Market Report 2015-2019

After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005- 2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.

Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China's economy develops, people's income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.

Key Topics Covered:

1 Related Concepts of Imatinib Mesylate

2 Market Profile of Imatinib Mesylate in China

3 Survey on Sales Status of Imatinib Mesylate in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Imatinib Mesylate in China, 2010-2014

5 Survey on Dosage Forms of Imatinib Mesylate in China, 2010-2014

6 Reference Price of Imatinib Mesylate in Chinese Hospitals in 2014

7 Major Manufacturers of Imatinib Mesylate in Chinese Market, 2010-2014

8 Market Outlook of Imatinib Mesylate in China, 2015-2019

Companies Mentioned

- Chia Tai Tianqing Pharmaceutical Group Co., Ltd

- Hansoh Pharmaceutical

- Novartis

For more information visit

http://www.researchandmarkets.com/research/6kp673/investigation

Media Contact:

Laura Wood, +353-1-481-1716, [email protected]